MedTrace Logo

Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis

NCT00587119 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2010-10-05

No results posted yet for this study

Summary

The purpose of the study is to find out the effects Budesonide, 9 mg daily for one year, has on patients with Primary Biliary Cirrhosis with features of autoimmune hepatitis.

Conditions

  • Primary Biliary Cirrhosis
  • Autoimmune Hepatitis

Interventions

DRUG

Budesonide

Oral Budesonide, 3 mg three times daily, will be given for 1 year.

Sponsors & Collaborators

Principal Investigators

  • Keith D Lindor, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587119 on ClinicalTrials.gov